IN2015DN04090A - - Google Patents

Download PDF

Info

Publication number
IN2015DN04090A
IN2015DN04090A IN4090DEN2015A IN2015DN04090A IN 2015DN04090 A IN2015DN04090 A IN 2015DN04090A IN 4090DEN2015 A IN4090DEN2015 A IN 4090DEN2015A IN 2015DN04090 A IN2015DN04090 A IN 2015DN04090A
Authority
IN
India
Prior art keywords
phosphorochloridate
ciu
nucleosides
nucleoside
salts
Prior art date
Application number
Inventor
Christopher Mcguigan
Fabrizio Pertusati
Original Assignee
Univ Cardiff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49622844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015DN04090(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1220666.0A external-priority patent/GB201220666D0/en
Priority claimed from GB201307314A external-priority patent/GB201307314D0/en
Application filed by Univ Cardiff filed Critical Univ Cardiff
Publication of IN2015DN04090A publication Critical patent/IN2015DN04090A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/06—Halogens; Compounds thereof
    • B01J27/128—Halogens; Compounds thereof with iron group metals or platinum group metals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01S—DEVICES USING THE PROCESS OF LIGHT AMPLIFICATION BY STIMULATED EMISSION OF RADIATION [LASER] TO AMPLIFY OR GENERATE LIGHT; DEVICES USING STIMULATED EMISSION OF ELECTROMAGNETIC RADIATION IN WAVE RANGES OTHER THAN OPTICAL
    • H01S5/00—Semiconductor lasers
    • H01S5/30—Structure or shape of the active region; Materials used for the active region
    • H01S5/34—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
    • H01S5/343—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser
    • H01S5/34326—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser with a well layer based on InGa(Al)P, e.g. red laser

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A process for preparing phosphoramidates of nucleosides where a desired enantiomer having regard to the asymmetric chiral centre of the phosphorus atom P is provided in an enriched amount. The process comprises admixing a nucleoside with a phosphorochloridate in the presence of a catalyst comprising a metal salt selected from the group consisting of salts of Ciu Fe La and Yb.
IN4090DEN2015 2012-11-16 2013-11-15 IN2015DN04090A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1220666.0A GB201220666D0 (en) 2012-11-16 2012-11-16 Process for preparing chemical compounds
GB201307314A GB201307314D0 (en) 2013-04-23 2013-04-23 Process for preparing chemical compounds
PCT/GB2013/053018 WO2014076490A1 (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs

Publications (1)

Publication Number Publication Date
IN2015DN04090A true IN2015DN04090A (en) 2015-10-09

Family

ID=49622844

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4090DEN2015 IN2015DN04090A (en) 2012-11-16 2013-11-15

Country Status (28)

Country Link
US (3) US10005810B2 (en)
EP (3) EP3235824B1 (en)
JP (5) JP2016506371A (en)
KR (1) KR20150103669A (en)
CN (2) CN111592577A (en)
AU (1) AU2013346515B2 (en)
CA (1) CA2891266C (en)
CL (1) CL2015001307A1 (en)
CY (2) CY1119161T1 (en)
DK (2) DK3235824T3 (en)
EA (1) EA028871B1 (en)
ES (3) ES2618732T3 (en)
HK (1) HK1210784A1 (en)
HR (2) HRP20170791T1 (en)
HU (2) HUE044605T2 (en)
IL (1) IL238792A (en)
IN (1) IN2015DN04090A (en)
LT (2) LT3235824T (en)
MX (1) MX2015006195A (en)
MY (1) MY176133A (en)
NZ (1) NZ708177A (en)
PH (1) PH12015501090A1 (en)
PL (2) PL3150616T3 (en)
PT (2) PT3150616T (en)
RS (2) RS56038B1 (en)
SG (3) SG11201503750YA (en)
SI (2) SI3150616T1 (en)
WO (1) WO2014076490A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
EA028871B1 (en) 2012-11-16 2018-01-31 Юниверсити Колледж Кардифф Консалтантс Лимитед Process for preparing chemical compounds
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
WO2015081133A2 (en) * 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. Nucleotides for the treatment of liver cancer
CN105153257B (en) * 2014-06-12 2019-03-05 正大天晴药业集团股份有限公司 The preparation method of Suo Feibuwei
TWI765176B (en) 2014-06-25 2022-05-21 英商努卡那公眾有限公司 Formulations of phosphate derivatives
CA2945938C (en) * 2014-06-25 2023-04-18 Nucana Biomed Limited Gemcitabine prodrugs
CN105254694B (en) * 2014-07-14 2018-11-27 正大天晴药业集团股份有限公司 Deuterated nucleoside derivates
ES2830784T3 (en) 2014-07-22 2021-06-04 NuCana plc Process for the preparation of gemcitabine- [phenyl (benzoxy-L-alanyl)] phosphate
CN106661074A (en) * 2014-07-31 2017-05-10 桑多斯股份公司 Synthesis of phosphoramidates
WO2016033164A1 (en) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN105461773B (en) * 2014-09-30 2020-12-01 江苏豪森药业集团有限公司 Preparation method and intermediate of sofosbuvir
CN105461774B (en) * 2014-09-30 2020-11-24 江苏豪森药业集团有限公司 Preparation method of sofosbuvir
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
US9718851B2 (en) 2014-11-06 2017-08-01 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
AU2016229966B2 (en) 2015-03-06 2018-09-27 Atea Pharmaceuticals, Inc. Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US10407456B2 (en) 2015-03-26 2019-09-10 Quimica Sintetica, S.A. Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof
CN106397515B (en) * 2015-07-28 2021-05-11 广东东阳光药业有限公司 Improved preparation method of Sofosbuvir
CN106539810B (en) * 2015-09-16 2021-03-09 济南高合医疗科技有限公司 Composition enriched in NUC-1031 single isomer, and preparation method and application thereof
CN106543220A (en) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 Phosphoramidate compounds and preparation method thereof and crystal
CN106543252A (en) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 The Preparation Method And Their Intermediate of nucleoside phosphoramidate class prodrug
KR20180063075A (en) * 2015-10-05 2018-06-11 뉴카나 피엘씨 Combination therapy
WO2017090264A1 (en) * 2015-11-27 2017-06-01 大原薬品工業株式会社 5'-position dibenzyl phosphoric acid ester of 5-azacytidine or 2'-deoxy body thereof
KR20180101370A (en) 2015-12-11 2018-09-12 뉴카나 피엘씨 Selective Synthesis of Diastereomers of Phosphate Derivatives and Gemcitabine Prodrug NUC-1031
GB201522771D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US10239910B2 (en) * 2016-07-20 2019-03-26 Optimus Drugs (P) Limited Process for the preparation of sofosbuvir
CN107652342A (en) * 2016-07-23 2018-02-02 江苏万高药业股份有限公司 Polymorphic of nucleoside phosphoramidate class prodrug and preparation method thereof
ES2907874T3 (en) 2016-09-07 2022-04-26 Atea Pharmaceuticals Inc 2'-substituted-N6-substituted purine nucleotides for the treatment of RNA viruses
US10266558B2 (en) * 2016-10-07 2019-04-23 Alexandre Vasilievich Ivachtchenko Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
EP3560943A4 (en) * 2016-12-23 2020-09-02 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nucleoside phosphate compound and preparation method and use thereof
CN115477679A (en) 2017-02-01 2022-12-16 阿堤亚制药公司 Nucleotide hemisulfate for the treatment of hepatitis C virus
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
JP2021521118A (en) 2018-04-10 2021-08-26 アテア ファーマシューティカルズ， インコーポレイテッド Treatment of HCV-infected patients with cirrhosis
WO2019237957A1 (en) 2018-06-12 2019-12-19 四川科伦博泰生物医药股份有限公司 Phosphonamide ester compound, salt thereof, related crystal form thereof, preparation method therefor and use thereof
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
RU2740058C1 (en) * 2020-06-26 2020-12-31 Общество С Ограниченной Ответственностью "Технология Лекарств" Method of producing sofosbuvir and phosphoramidates
CN112409431B (en) * 2020-12-07 2023-04-21 武汉伯瑞恒医药科技有限公司 Cytarabine structural analogue, and preparation method and application thereof
CN113549076B (en) * 2021-07-23 2022-12-06 中国药科大学 Polysubstituted purine compound and preparation method and application thereof
WO2024107859A1 (en) * 2022-11-15 2024-05-23 Rome Therapeutics, Inc. Cyclopentene-oxymethylene phosphonamidates and related compounds and their use in treating medical conditions

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5827727A (en) 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US6245750B1 (en) 1998-01-23 2001-06-12 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
NZ534811A (en) 2002-02-14 2007-07-27 Pharmasset Inc Modified fluorinated nucleoside analogues
WO2004041203A2 (en) 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
JP2009504704A (en) * 2005-08-15 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー Antiviral 4'-substituted pronucleotide phosphoramidate
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
PA8852101A1 (en) * 2008-12-08 2010-07-27 Medivir Ab URACIL CYCLOPROPYLL NUCLEOTIDES
SG172921A1 (en) * 2009-01-09 2011-08-29 Univ Cardiff Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
TWI583692B (en) * 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
SI2609923T1 (en) * 2010-03-31 2017-10-30 Gilead Pharmasset Llc Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
KR102108864B1 (en) * 2010-07-19 2020-05-12 길리애드 사이언시즈, 인코포레이티드 Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
US8871737B2 (en) * 2010-09-22 2014-10-28 Alios Biopharma, Inc. Substituted nucleotide analogs
CA2819041A1 (en) * 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
LT3447061T (en) * 2011-03-01 2022-01-25 NuCana plc Pharmaceutical formulation comprising a phosphoramidate derivative of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
CN103635196B (en) * 2011-03-02 2019-05-07 J·深塔格 For fatty degeneration of liver or treatment to be used individually with adipohepatic composition, treatment method and the diagnostic method of infection with hepatitis C virus
WO2013056132A2 (en) * 2011-10-14 2013-04-18 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
EA028871B1 (en) * 2012-11-16 2018-01-31 Юниверсити Колледж Кардифф Консалтантс Лимитед Process for preparing chemical compounds
US9815864B2 (en) * 2013-06-26 2017-11-14 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
ES2927955T3 (en) 2013-09-11 2022-11-14 Univ Emory Nucleotide and Nucleoside Compositions and Their Uses
CA2927010C (en) * 2013-10-11 2022-06-07 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015081133A2 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. Nucleotides for the treatment of liver cancer
KR20160079846A (en) * 2013-11-27 2016-07-06 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Piperidine and piperazine derivatives and their use in treating viral infections and cancer
TWI765176B (en) 2014-06-25 2022-05-21 英商努卡那公眾有限公司 Formulations of phosphate derivatives
CA2945938C (en) 2014-06-25 2023-04-18 Nucana Biomed Limited Gemcitabine prodrugs
ES2830784T3 (en) 2014-07-22 2021-06-04 NuCana plc Process for the preparation of gemcitabine- [phenyl (benzoxy-L-alanyl)] phosphate
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
MY192081A (en) 2015-05-14 2022-07-26 NuCana plc Cancer treatments
KR20180063075A (en) 2015-10-05 2018-06-11 뉴카나 피엘씨 Combination therapy
KR20180101370A (en) 2015-12-11 2018-09-12 뉴카나 피엘씨 Selective Synthesis of Diastereomers of Phosphate Derivatives and Gemcitabine Prodrug NUC-1031
US20190381084A1 (en) 2015-12-23 2019-12-19 Nucana Biomed Limited Combination therapy
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
EP3738595A1 (en) 2015-12-23 2020-11-18 Nucana PLC Combination therapy
GB201713914D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Combination therapy

Also Published As

Publication number Publication date
CY1121663T1 (en) 2020-07-31
LT3150616T (en) 2017-07-25
US20180273575A1 (en) 2018-09-27
EP3150616B1 (en) 2017-05-10
HRP20190831T1 (en) 2019-08-23
JP7519259B2 (en) 2024-07-19
US20220033433A1 (en) 2022-02-03
AU2013346515A1 (en) 2015-06-04
JP2019196360A (en) 2019-11-14
HUE044605T2 (en) 2019-11-28
EP2920192B1 (en) 2017-02-22
PT3150616T (en) 2017-06-09
CN111592577A (en) 2020-08-28
SG10201510322UA (en) 2016-01-28
KR20150103669A (en) 2015-09-11
US10005810B2 (en) 2018-06-26
JP2018009000A (en) 2018-01-18
EP3150616A1 (en) 2017-04-05
EP3235824B1 (en) 2019-03-27
SG10201510324YA (en) 2016-01-28
BR112015011155A2 (en) 2017-07-11
CY1119161T1 (en) 2018-02-14
SG11201503750YA (en) 2015-06-29
CL2015001307A1 (en) 2015-12-11
JP2021020919A (en) 2021-02-18
HK1210784A1 (en) 2016-05-06
SI3150616T1 (en) 2017-08-31
AU2013346515B2 (en) 2017-05-25
CN104903339A (en) 2015-09-09
PT3235824T (en) 2019-05-30
CA2891266A1 (en) 2014-05-22
EP3235824A1 (en) 2017-10-25
PH12015501090B1 (en) 2015-07-27
HRP20170791T1 (en) 2017-08-25
HUE033335T2 (en) 2017-11-28
MX2015006195A (en) 2015-12-08
US11040997B2 (en) 2021-06-22
NZ708177A (en) 2017-08-25
WO2014076490A1 (en) 2014-05-22
LT3235824T (en) 2019-07-10
EP2920192A1 (en) 2015-09-23
IL238792A0 (en) 2015-06-30
ES2618732T3 (en) 2017-06-22
JP2023052536A (en) 2023-04-11
ES2725491T3 (en) 2019-09-24
DK3235824T3 (en) 2019-05-20
ES2627195T3 (en) 2017-07-27
CA2891266C (en) 2020-12-08
DK3150616T3 (en) 2017-06-06
EA201590955A1 (en) 2015-08-31
US20150291650A1 (en) 2015-10-15
PL3235824T3 (en) 2019-09-30
SI3235824T1 (en) 2019-08-30
MY176133A (en) 2020-07-24
EA028871B1 (en) 2018-01-31
IL238792A (en) 2017-09-28
RS58849B1 (en) 2019-07-31
JP2016506371A (en) 2016-03-03
PL3150616T3 (en) 2017-09-29
PH12015501090A1 (en) 2015-07-27
RS56038B1 (en) 2017-09-29

Similar Documents

Publication Publication Date Title
IN2015DN04090A (en)
ZA201409013B (en) Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
IL228680A0 (en) 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
PL2796555T3 (en) Method for producing l-lysine using microorganisms having ability to produce l-lysine
EP2674395A4 (en) Process for production of fluorosulfonylimide ammonium salt
PL2794628T3 (en) 4'-azido-3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
EA033455B1 (en) Crystalline forms of substituted 5-fluoro-1h-pyrazolopyridines, processes for preparing same, use thereof for producing a medicament, medicament and method of treatment based thereof
ZA201503644B (en) Antiviral phosphonate analogues and process for preparation thereof
MX2012000583A (en) Method for producing chiral 3-triazolyl-sulfoxide derivatives.
HK1249505A1 (en) Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors
IL235922B (en) Production of ammonium phosphates
TN2013000369A1 (en) Preventing or reducing scale in wet-process phosphoric acid production
EP2822574A4 (en) Methods for modulation of phosphorus and fgf23
PL2675910T3 (en) Process for the production of a composition containing 5'-ribonucleotides
EP2834190A4 (en) Process for production of hypophosphite salts
PL2665734T3 (en) METHOD FOR THE MANUFACTURE OF COMPOUNDS CONTAINING AN alpha-OXY PHOSPHORUS GROUP
MX2013007481A (en) Method for controlling phytopathogenic fungi.
PL2687536T3 (en) Method for producing asymmetric (thio)phosphate triamides
SG11201402507YA (en) Method for producing high-purity crystalline carbamide
EP2799440A4 (en) Preparation method of 3,7,11-trimethyldodec-2,4,6,10-tetraene-1-yl phosphonic salt
RS56101B1 (en) 4'-azido-3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
JO3153B1 (en) Preventing or reducing scale in wet-process phosphoric acid production
HUP1200665A2 (en) Process for production of soil nutrient supplying agent
UA75618U (en) Process for the preparation of potassium nitrate and magnesium chloride from potassium chloride and magnesium nitrate